Table II.
Analysis of clinicopathological and genotypic parameters for overall survival in 112 patients with cholangiocarcinoma receiving surgery.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Parameters | No. of patients | Mean overall survival time (95% CI) | Hazard ratio (95% CI) | P-value | Adjusted hazard ratio (95% CI) | P-value |
| Age (years) | 0.732 | |||||
| ≤60 | 57 | 98.5 (69.4–127.4) | ||||
| >60 | 55 | 89.9 (68.6–111.6) | 1.138 (0.544–2.544) | |||
| Sex | 0.964 | |||||
| Female | 50 | 81.8 (57.3–106.3) | ||||
| Male | 62 | 108.6 (78.3–139.3) | 0.983 (0.472–2.472) | |||
| HBsAg | 0.055 | |||||
| Negative | 86 | 73.2 (54.1–92.1) | ||||
| Positive | 26 | 138.2 (103.3–173.3) | 0.346 (0.117–1.117) | |||
| Anti-HCV | 0.278 | |||||
| Negative | 97 | 95.2 (71.6–118.6) | ||||
| Positive | 15 | 64.7 (51.1–78.1) | 0.450 (0.106–1.106) | |||
| Cirrhosis | 0.341 | |||||
| No | 93 | 96.1 (72.1–120.1) | ||||
| Yes | 19 | 74.1 (54.7–93.7) | 0.558 (0.168–1.168) | |||
| ECOG stage | 0.062 | |||||
| 0 | 68 | 109.5 (83.8–135.8) | ||||
| >0 | 44 | 37.7 (20.9–54.9) | 2.135 (0.964–4.964) | |||
| Biliary tree stones | 0.092 | |||||
| No | 88 | 106.4 (81.9–130.9) | ||||
| Yes | 24 | 37.9 (13.1–62.1) | 2.130 (0.883–5.883) | |||
| Cholangitis (stone-unrelated) | 0.081 | |||||
| No | 66 | 76.1 (53.6–98.6) | ||||
| Yes | 46 | 118.6 (84.8–152.8) | 0.491 (0.221–1.221) | |||
| Tumor characteristics Location | 0.157 | |||||
| Intrahepatic | 87 | 102.8 (74.9–130.9) | ||||
| Perihilar | 25 | 68.2 (38.4–97.4) | 1.742 (0.808–3.808) | |||
| Invasion to vessels | 0.010c | 0.002c | ||||
| No | 82 | 109.2 (83.9–134.9) | ||||
| Yes | 30 | 39.8 (25.5–54.5) | 2.838 (1.285–6.285) | 3.853 (1.624–9.624) | ||
| Perineural invasion | <0.001c | 0.001c | ||||
| No | 64 | 141.6 (115.0–168.0) | ||||
| Yes | 48 | 51.6 (29.8–73.8) | 4.812 (2.126–10.126) | 5.086 (1.894–13.894) | ||
| Periductal invasion | 0.997 | |||||
| No | 67 | 99.3 (71.2–127.2) | ||||
| Yes | 45 | 85.3 (59.5–111.5) | 1.002 (0.472–2.472) | |||
| Lymph node involvement | <0.001c | 0.308 | ||||
| No | 79 | 119.3 (92.1–146.1) | ||||
| Yes | 33 | 45.5 (15.6–75.6) | 3.756 (1.796–7.796) | 1.645 (0.632–4.632) | ||
| Tumor number | ||||||
| 1 | 101 | 105.8 (82.1–129.1) | ||||
| >1 | 11 | 68.1 (27.9–108.9) | 1.361 (0.471–3.471) | |||
| Largest tumor size (cm) | 0.008a | 0.113 | ||||
| ≤5.25 | 56 | 116.5 (86.5–146.5) | ||||
| >5.25 | 56 | 69.0 (38.8–99.8) | 2.839 (1.306–6.306) | 2.147 (0.835–5.835) | ||
| Histology | 0.654 | |||||
| Well differentiated | 25 | 65.0 (49.0–81.0) | ||||
| Moderate/poorly differentiated | 87 | 96.3 (71.5–121.5) | 1.249 (0.472–3.472) | |||
| Mixed hepatocellular carcinoma | 0.126 | |||||
| No | 98 | 85.1 (64.1–106.1) | ||||
| Yes | 14 | 0.037 (0.001–2.001) | ||||
| Extrahepatobiliary invasion | b | 0.268 | ||||
| No | 66 | 102.3 (75.5–129.5) | ||||
| Yes | 46 | 85.9 (59.9–111.9) | 1.532 (0.720–3.720) | |||
| Resection margin | 0.015c | 0.180 | ||||
| R0 | 68 | 113.3 (87.4–139.4) | ||||
| R1 | 44 | 37.8 (26.1–49.1) | 2.654 (1.207–5.207) | 1.736 (0.776–3.776) | ||
| Resection method | 0.993 | |||||
| Mono-segmental | 14 | 58.1 (33.8–82.8) | ||||
| >1 segment | 98 | 101.7 (77.6–125.6) | 1.005 (0.346–2.346) | |||
| Biochemistry CEA (ng/ml)a | <0.001c | |||||
| ≤5.1 | 36 | 133.8 (102.5–165.5) | ||||
| >5.1 | 33 | 47.6 (20.6–74.6) | 6.069 (2.332–15.332) | |||
| CA-19-9 (U/ml)a | <0.001c | |||||
| ≤107 | 41 | 139.4 (111.0–167.0) | ||||
| >107 | 29 | 29.7 (15.8–43.8) | 14.531 (4.195–50.195) | |||
| Bilirubin (mg/dl) | 0.371 | |||||
| ≤0.9 | 59 | 97.2 (71.5–123.5) | ||||
| >0.9 | 53 | 100.1 (67.3–133.3) | 1.396 (0.642–2.642) | |||
| AST (U/l) | 0.356 | |||||
| ≤31.5 | 56 | 103.0 (73.6–132.6) | ||||
| >31.5 | 56 | 92.2 (62.8–121.8) | 1.415 (0.677–2.677) | |||
| ALT (U/l) | 0.087 | |||||
| ≤32.0 | 58 | 115.6 (84.7–146.7) | ||||
| >32.0 | 54 | 79.7 (51.6–107.6) | 1.926 (0.908–4.908) | |||
| Chemotherapy | 0.577 | |||||
| No | 72 | 15.6 (2.2–29.2) | ||||
| Yes | 40 | 33.2 (6.7–59.7) | 0.807 (0.380–1.380) | |||
| GALNT14 genotype | 0.027c | 0.897 | ||||
| Non-TT | 77 | 113.6 (86.0–141.0) | ||||
| TT | 35 | 71.6 (39.1–104.1) | 2.282 (1.098–4.098) | 0.948 (0.424–2.424) | ||
CI, confidence interval; HBsAg, hepatitis B virus surface antigen; HCV, hepatitis C virus; ECOG, Eastern Co-operative Oncology Group; CEA, carcinoembryonic antigen; CA-19-9, carbohydrate antigen 19-9; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
a
Missing data noted
b
All survived during follow-ups
c
P<0.05.